Professor Matt Whiteman

Matt Whiteman is Professor of Experimental Therapeutics at the University of Exeter Medical School, UK. His research focuses on developing novel small-molecule approaches to modulate cellular bioenergetics for the treatment of immunometabolic and primary mitochondrial disorders. In 2021, he co-founded the University of Exeter spinout company MitoRx Therapeutics, which develops first-in-class therapeutics for metabolic disease. The company is pursuing small-molecule candidates that enhance muscle function and promote weight loss while preserving and improving lean mass in obesity and related cardiometabolic conditions. His presentation will highlight recent advances at Exeter in small-molecule strategies to prevent or restore skeletal muscle integrity and insulin sensitivity in metabolic atrophy.